Introduction
============

Metabolic syndrome (MetS) is well known as a risk factor for cardiovascular disease. Visceral fat as a fundamental characteristic of MetS is associated with an increase in future insulin resistance[@b1]. Furthermore, it has been reported that MetS is one of the risk factors for the development of type 2 diabetes in different ethnic populations[@b2]--[@b12], but only limited data are available on the association between MetS and the risk of type 2 diabetes among the Japanese population[@b13].

Several organizations have proposed criteria for MetS[@b14]--[@b17]. Among these, in the criteria developed by the International Diabetes Federation (IDF)[@b14] and the Japanese Society of Internal Medicine (Japanese criteria)[@b15], central obesity is defined as an essential component. In contrast, in the criteria formulated by the World Health Organization[@b16] and the American Heart Association/National Heart, Lung and Blood Institute Scientific Statement (AHA/NHLBI)[@b17], central obesity is not defined as an essential component. Controversy has thus surrounded the decision about whether or not the central obesity component should be regarded as a prerequisite for diagnosis of MetS. In addition, no information has been published regarding the association between MetS and the future development of type 2 diabetes on the basis of the presence or absence of central obesity.

Since 1970, we have carried out a comparative medical survey of Japanese Americans immigrating to the USA and native Japanese living in Japan (called the Hawaii--Los Angeles--Hiroshima Study). This project represents a long-term epidemiological study of Japanese Americans who are genetically equivalent to native Japanese living in Japan, but who have undergone a rapid and intense Westernization of lifestyle[@b18]. We have shown through the survey that Japanese Americans have high levels of insulin resistance, and increased total cholesterol and triglycerides, thereby showing that a Westernized lifestyle aggravates atherosclerosis risk factors[@b19]. In addition, we have reported that a Westernized lifestyle promotes the development of diabetes as a result of insulin resistance[@b20], and increases the prevalence of MetS among Japanese Americans as compared with native Japanese living in Japan[@b21]. These results suggest that MetS might increase the prevalence of type 2 diabetes as well as atherosclerosis in Japanese Americans. We therefore investigated the impact of MetS and its individual components, particularly central obesity, with regard to the incidence of type 2 diabetes among Japanese Americans living in Hawaii and Los Angeles.

Materials and Methods
=====================

Participants
------------

Study participants were Japanese Americans enrolled two or more times in the Hawaii--Los Angeles--Hiroshima Study between 1992 and 2007. The study population consisted of 379 men and 549 women who did not have diabetes, as ascertained by a 75-g oral glucose tolerance test (OGTT) at baseline. Participants who had a medical history of gastric resection were excluded from the present study. Written informed consent was obtained from all participants. This study was approved by the ethics committee of Hiroshima University, and the Councils of the Hiroshima Kenjin-Kai Associations in Hawaii and Los Angeles.

Measurements
------------

In the morning after an overnight fast, each participant underwent an interview, physical and blood pressure measurements, and venous blood sampling. Body mass index was calculated as weight in kilograms divided by the square of height in meters. Waist circumference was measured at the level of the umbilicus. An OGTT was then carried out at the time of each follow-up examination, and participants were examined at least twice during the study periods. We used the 2003 American Diabetes Association criteria for diabetes and impaired glucose tolerance (IGT)[@b22]. Each blood sample was centrifuged, and the obtained serum samples were immediately frozen and stored until analysis. Serum glucose levels were measured by the hexokinase method, insulin levels by a double-antibody radioimmunoassay, triglyceride levels by an enzymatic method, and total and high density lipoprotein (HDL) cholesterol levels by the immunoinhibition method. Insulin resistance was evaluated by homeostasis model assessment of insulin resistance (HOMA-IR).

Diagnostic Criteria for Metabolic Syndrome
------------------------------------------

MetS was diagnosed according to the AHA/NHLBI[@b17], with waist circumferences modified for Asian populations in accordance with the IDF definition of MetS[@b14]. MetS was diagnosed when three or more of the following components were present: (i) central obesity (waist circumference ≥90 cm in men and ≥80 cm in women); (ii) high blood pressure (systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg and/or current use of medication for hypertension); (iii) high triglyceride (triglyceride ≥150 mg/dL and/or current use of medication for dyslipidemia); (iv) low HDL cholesterol (HDL cholesterol \<40 mg/dL in men or \<50 mg/dL in women and/or current use of medication for dyslipidemia); and (v) impaired fasting glycemia (IFG; fasting glucose ≥100 mg/dL).

Statistical Analysis
--------------------

Statistical analysis was carried out using the Statistical Package for Social Science (version 12.0 for Windows; SPSS, Chicago, IL, USA). Data were expressed as means ± standard deviation. Categorized data were analyzed by χ^2^-test, and unpaired Student\'s *t*-tests were used for group comparisons (with MetS vs without MetS). Before analysis, the skewed distribution of fasting insulin, HOMA-IR and triglyceride was normalized by logarithmic transformation. Multivariate-adjusted hazard ratios (HRs) and their 95% CIs were estimated with the use of the Cox proportional hazards model. *P* \< 0.05 was considered statistically significant in all analyses.

Results
=======

Baseline characteristics divided into two groups of individuals with or without MetS are shown in Table [1](#tbl1){ref-type="table"}. There was no significant difference in sex ratio. However, in the group with MetS compared with the group without MetS, age, body mass index, waist circumference, systolic blood pressure, diastolic blood pressure, fasting glucose, 2-h glucose, fasting insulin, 2-h insulin, HOMA-IR, total cholesterol, triglycerides and IGT ratio were significantly higher, and HDL cholesterol was lower.

###### 

Baseline characteristics of the subjects divided by individuals with or without metabolic syndrome

                                                            With MetS       Without MetS   *P*
  --------------------------------------------------------- --------------- -------------- ---------
  Men/women                                                 137/170         242/379        0.103
  Age (years)                                               63.7 ± 11.6     59.3 ± 14.1    \<0.001
  Body mass index (kg/m^2^)                                 25.8 ± 3.5      22.5 ± 3.2     \<0.001
  Waist circumference (cm)                                  84.6 ± 9.0      75.5 ± 8.4     \<0.001
  Systolic blood pressure (mmHg)                            139 ± 13.8      128.0 ± 17.0   \<0.001
  Diastolic blood pressure (mmHg)                           78.1 ± 10.2     72.6 ± 9.9     \<0.001
  Fasting glucose (mg/dL)                                   93.4 ± 11.3     85.4 ± 9.3     \<0.001
  2-h glucose (mg/dL)                                       129.5 ± 30.6    105.5 ± 30.1   \<0.001
  Fasting insulin (μU/mL)[†](#tf1-1){ref-type="table-fn"}   10.2 ± 6.3      6.2 ± 3.7      \<0.001
  2-h insulin (μU/mL)[†](#tf1-1){ref-type="table-fn"}       80.4 ± 57.7     49.5 ± 42.6    \<0.001
  HOMA-IR[†](#tf1-1){ref-type="table-fn"}                   2.4 ± 1.6       1.3 ± 0.9      \<0.001
  Total cholesterol (mg/dL)                                 230.3 ± 37.8    220.5 ± 36.4   \<0.001
  Triglycerides (mg/dL)[†](#tf1-1){ref-type="table-fn"}     239.1 ± 187.6   118 ± 69.5     \<0.001
  HDL cholesterol (mg/dL)                                   44.1 ± 13.6     57.0 ± 13.5    \<0.001
  Impaired glucose tolerance (%)                            117 (56.0)      190 (26.4)     \<0.001
  Developed to diabetes (%)                                 67 (21.8)       49 (7.9)       \<0.001

MetS, metabolic syndrome; HOMA-IR, homeostasis model assessment of insulin resistance; HDL, high density lipoprotein. Data are expressed as means ± SD. *P* values are determined by unpaired *t* test or χ^2^ test.

Parameters are transformed logarithmically before analysis.

A total of 116 participants developed type 2 diabetes during the follow-up period (6.8 ± 0.1 years). The Cox proportional hazards model was used to examine the association between MetS or its individual components and the development of type 2 diabetes (Table [2](#tbl2){ref-type="table"}). MetS was a significant risk factor for type 2 diabetes (HR 3.08, 95% CI 2.13--4.46, *P* \< 0.001). All individual components of MetS, except for high triglycerides, were also associated with a significantly increased risk of type 2 diabetes. The multivariate analysis for prediction of type 2 diabetes associated with MetS or its individual components after adjustment for sex, age and IGT is shown in Table [2](#tbl2){ref-type="table"}. Only IFG (HR 2.28, 95% CI 1.51--3.44, *P* \< 0.001) among the five components and MetS (HR 1.64, 95% CI 1.11--2.42, *P* \< 0.001) were significantly associated with incident type 2 diabetes. Other individual components as well as central obesity were not independent risk factors for the development of type 2 diabetes. Baseline characteristics of the participants divided by individuals with or without central obesity and MetS are shown in Table [3](#tbl3){ref-type="table"}. In this analysis, MetS was defined as the presence of at least three metabolic syndrome components, not including the component of central obesity. The participants with central obesity and without MetS had higher body mass index, waist circumference, systolic blood pressure, diastolic blood pressure, fasting glucose, 2-h glucose, fasting insulin, 2-h insulin, HOMA-IR and triglyceride, and had lower HDL cholesterol compared with participants without both central obesity and MetS. The participants with MetS, regardless of central obesity, were significantly older and had higher body mass index, waist circumference, systolic blood pressure, diastolic blood pressure, fasting glucose, 2-h glucose, fasting insulin, 2-h insulin, HOMA-IR, total cholesterol, triglycerides and IGT ratio, and had lower HDL cholesterol compared with participants without both central obesity and MetS. We next examined the combined and separate effects of central obesity and MetS on incident type 2 diabetes. The participants with central obesity without MetS did not have significantly higher HR of incident type 2 diabetes (HR 0.98, 95% CI 0.52--1.83, *P* = 0.939) compared with those without both central obesity and MetS. However, those with MetS had a significantly higher HR of incident type 2 diabetes with or without central obesity (HR 4.17, 95% CI 2.60--6.70, *P* \< 0.001; HR 3.68, 95% CI 2.25--5.99, *P* \< 0.001), respectively. After adjusting for sex, age and IGT, the participants with central obesity but without MetS did not have a significantly higher HR of incident type 2 diabetes (HR 0.85, 95% CI 0.45--1.60, *P* = 0.612) compared with those without central obesity and without MetS (Figure [1](#fig01){ref-type="fig"}). However, those with MetS had a significantly higher HR of incident type 2 diabetes with or without central obesity (HR 2.46, 95% CI 1.51--4.01, *P* \< 0.001; HR 2.07, 95% CI 1.25--3.41, *P* = 0.004), respectively.

###### 

HRs for the development of type 2 diabetes associated with metabolic syndrome and its individual components

                                                                                                   Crude HR (95% CI)   *P*       Multivariate-adjusted HR (95% CI)   *P*
  ------------------------------------------------------------------------------------------------ ------------------- --------- ----------------------------------- ---------
  Presence of MetS                                                                                 3.08 (2.13--4.46)   \<0.001   1.64 (1.11--2.42)                   \<0.001
  Central obesity (waist circumference ≥90 cm \[men\], ≥80 cm \[women\])                           1.96 (1.35--2.85)   \<0.001   1.28 (0.87--1.88)                   0.214
  High blood pressure (BP) (BP ≥ 130/85 mmHg or medication use)                                    2.16 (1.41--3.30)   \<0.001   1.21 (0.76--1.92)                   0.424
  High triglycerides (TG) (TG ≥ 150 mg/dL or medication use)                                       1.35 (0.94--1.90)   0.108     0.85 (0.58--1.24)                   0.393
  Low HDL cholesterol (HDL-C) (HDL-C \<40 mg/dL \[men\], \<50 mg/dL \[women\] or medication use)   1.61 (1.12--2.32)   0.010     1.27 (0.88--1.83)                   0.207
  Impaired fasting glycemia (fasting glucose ≥100 mg/dL)                                           5.26 (3.61--7.67)   \<0.001   2.28 (1.51--3.44)                   \<0.001

Multivariate adjustment was made for sex, age, and IGT. HR, hazards ratio; CI, confidence interval; MetS, metabolic syndrome.

###### 

Baseline characteristics of the subjects divided by individuals with or without central obesity and metabolic syndrome

                                                            Without central obesity, without MetS   With central obesity, without MetS               Without central obesity, with MetS               With central obesity, with MetS
  --------------------------------------------------------- --------------------------------------- ------------------------------------------------ ------------------------------------------------ ------------------------------------------------
  Men/Women                                                 187/283                                 78/112                                           65/77                                            49/77
  Age (years)                                               59.6 ± 14.5                             60.2 ± 13.7                                      63.6 ± 11.5[\*](#tf3-2){ref-type="table-fn"}     62.8 ± 10.3[\*](#tf3-2){ref-type="table-fn"}
  Body mass index (kg/m^2^)                                 21.9 ± 2.8                              26.2 ± 3.4[\*](#tf3-2){ref-type="table-fn"}      22.9 ± 2.6[\*](#tf3-2){ref-type="table-fn"}      26.9 ± 3.3[\*](#tf3-2){ref-type="table-fn"}
  Waist circumference (cm)                                  74.2 ± 7.8                              84.7 ± 9.4[\*](#tf3-2){ref-type="table-fn"}      77.4 ± 7.2[\*](#tf3-2){ref-type="table-fn"}      86.3 ± 8.8[\*](#tf3-2){ref-type="table-fn"}
  Systolic blood pressure (mmHg)                            128.4 ± 17.0                            132.2 ± 16.3[\*](#tf3-2){ref-type="table-fn"}    139.0 ± 17.4[\*](#tf3-2){ref-type="table-fn"}    134.8 ± 12.7[\*](#tf3-2){ref-type="table-fn"}
  Diastolic blood pressure (mmHg)                           72.6 ± 10.1                             74.5 ± 10.1[\*](#tf3-2){ref-type="table-fn"}     78.3 ± 10.3[\*](#tf3-2){ref-type="table-fn"}     76.8 ± 9.8[\*](#tf3-2){ref-type="table-fn"}
  Fasting glucose (mg/dL)                                   85.7 ± 9.9                              88.2 ± 10.8[\*](#tf3-2){ref-type="table-fn"}     90.9 ± 11.0[\*](#tf3-2){ref-type="table-fn"}     93.3 ± 10.4[\*](#tf3-2){ref-type="table-fn"}
  2-h glucose (mg/dL)                                       105.1 ± 30.4                            114.2 ± 29.7[\*](#tf3-2){ref-type="table-fn"}    126.1 ± 32.8[\*](#tf3-2){ref-type="table-fn"}    129.4 ± 31.7[\*](#tf3-2){ref-type="table-fn"}
  Fasting insulin (μU/mL)[†](#tf3-2){ref-type="table-fn"}   5.9 ± 3.1                               9.0 ± 5.8[\*](#tf3-2){ref-type="table-fn"}       7.9 ± 4.6[\*](#tf3-2){ref-type="table-fn"}       11.1 ± 7.5[\*](#tf3-2){ref-type="table-fn"}
  2-h insulin (μU/mL)[†](#tf3-2){ref-type="table-fn"}       47.1 ± 36.4                             68.2 ± 58.7[\*](#tf3-2){ref-type="table-fn"}     64.2 ± 39.2[\*](#tf3-2){ref-type="table-fn"}     88.8 ± 71.9[\*](#tf3-2){ref-type="table-fn"}
  HOMA-IR[†](#tf3-2){ref-type="table-fn"}                   1.3 ± 0.8                               2.0 ± 1.4[\*](#tf3-2){ref-type="table-fn"}       1.8 ± 1.2[\*](#tf3-2){ref-type="table-fn"}       2.6 ± 1.9[\*](#tf3-2){ref-type="table-fn"}
  Total cholesterol (mg/dL)                                 220.3 ± 37.3                            223.6 ± 35.4                                     229.1 ± 35.2[\*](#tf3-2){ref-type="table-fn"}    230.6 ± 39.7[\*](#tf3-2){ref-type="table-fn"}
  Triglycerides (mg/dL)[†](#tf3-2){ref-type="table-fn"}     123.8 ± 86.1                            157.7 ± 160.7[\*](#tf3-2){ref-type="table-fn"}   226.4 ± 172.5[\*](#tf3-2){ref-type="table-fn"}   209.5 ± 146.3[\*](#tf3-2){ref-type="table-fn"}
  HDL cholesterol (mg/dL)                                   56.6 ± 14.2                             51.2 ± 12.5[\*](#tf3-2){ref-type="table-fn"}     46.8 ± 15.3[\*](#tf3-2){ref-type="table-fn"}     47.2 ± 15.7[\*](#tf3-2){ref-type="table-fn"}
  Impaired glucose tolerance (%)                            68 (14.5)                               38 (20.0)                                        55 (38.7)[\*](#tf3-2){ref-type="table-fn"}       48 (38.1)[\*](#tf3-2){ref-type="table-fn"}
  Developed to diabetes (%)                                 32 (6.8)                                14 (7.4)                                         33 (23.2)[\*](#tf3-2){ref-type="table-fn"}       37 (29.4)[\*](#tf3-2){ref-type="table-fn"}

Data are expressed as means ± SD. *P* values are determined by unpaired t-test or χ^2^ test.

Parameters are transformed logarithmically before analysis. MetS, metabolic syndrome; HOMA-IR, homeostasis model assessment of insulin resistance; HDL, high density lipoprotein.

*P* \< 0.05 compared to by individuals without central obesity and without MetS.

![Multivariate-adjusted hazard ratios (HRs) for the development of type 2 diabetes according to the presence or absence of metabolic syndrome (MetS) and central obesity. MetS was defined as the presence of at least three MetS components, not including the component of central obesity. Multivariate adjustment was made for sex, age and impaired glucose tolerance. The centers of the boxes are placed at the estimates of HRs. Error bars indicate 95% confidence intervals (CIs).](jdi0006-0527-f1){#fig01}

Discussion
==========

In the present study, even when participants were stratified by the presence or absence of central obesity, MetS as defined by AHA/NHLBI diagnostic criteria was a significant predictor of type 2 diabetes in a Japanese American population. This result suggests that central obesity is not the indispensable component of MetS for detecting the risk of type 2 diabetes.

In the present study, IFG and MetS itself remained as factors that were significantly associated with an increased risk of incident type 2 diabetes after adjustment for sex, age and IGT. In several studies, IFG was known to be the strongest predictor of type 2 diabetes among the components[@b8],[@b13],[@b23]--[@b25]. We therefore showed that MetS is an important predictor of type 2 diabetes among Japanese Americans, as is the case with IFG.

Ford *et al*.[@b23] reported that MetS was a factor in increased risk of incident type 2 diabetes in Europeans, and that central obesity as well as IFG in particular among the components of MetS were strong factors. Central obesity has been reported as an important factor in the development of type 2 diabetes[@b26],[@b27], and is defined as an essential component in some MetS diagnostic criteria, such as those of the IDF[@b14] or the Japanese criteria[@b15]. However, in the present study, MetS was not considered a significant risk factor for incident type 2 diabetes after adjustment for sex, age, and IGT when using the IDF and Japanese criteria (*P* = 0.074 and *P* = 0.270, respectively; data not shown). The reason for this is that waist circumference might not accurately reflect visceral fat in East Asians. Insulin resistance and risk of type 2 diabetes were reported to be increased by the accumulation of visceral fat, but not subcutaneous fat in Japanese Americans[@b1]. However, despite lower levels of overall adiposity, participants in East Asia, mainly Japan, Korea and China, were characterized by a larger relative visceral adipose tissue accumulation than any other ethnic group[@b28]. Therefore, central obesity might not accurately express the risk of type 2 diabetes among our study\'s Japanese American population.

The present study had several limitations. First, we did not evaluate family history, drinking habits, educational status or physical activity, all of which are well-known risk factors for type 2 diabetes. Second, there was a lack of data regarding inflammation and smoking status of the participants. Third, the thresholds of waist circumference for Asians according to the IDF MetS definition used in the present study might not be applicable to a Japanese population. However, the result did not change even when the thresholds of waist circumference in the Japanese criteria (≥85 cm in men and ≥90 cm in women) were used instead of those indicated in the IDF definition for Asians (≥90 cm in men and ≥80 cm in women; data not shown). Further studies are required to determine the appropriate thresholds for assessing the risk of type 2 diabetes in the Japanese population.

In summary, the present study showed that the overlap of multiple risk factors regardless of central obesity was a significant predictor of type 2 diabetes. Accordingly, the AHA/NHLBI diagnostic criteria for MetS could be more useful than other criteria in evaluating the risk of type 2 diabetes in Japanese Americans, and MetS is recognized as a risk factor of cardiovascular disease.
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